Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale under a pre-arranged plan. She exercised stock options for 2,176 shares of common stock at $3.98 per share and sold 2,176 shares in an open-market transaction at $19.00 per share, all on June 17, 2026 pursuant to a Rule 10b5-1 trading plan adopted on February 19, 2026. Following these transactions, she directly owns 62,371 common shares and holds 33,473 stock options.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson exercised options for 3,000 shares of common stock at $6.14 per share and on the same day sold 3,000 shares at $19.00 per share in an open-market transaction. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following the sale, Townson directly holds 67,845 common shares, along with 206,290 stock options that remain outstanding.
GLUE submitted a Form 144 notice reporting planned and recent transactions in Common Stock. The notice lists 2,176 shares associated with an exercise of stock options and a proposed sale on 06/17/2026 for cash. It also discloses prior sales by Jennifer Champoux of 2,176 shares on 05/22/2026 and 2,175 shares on 05/27/2026, with reported amounts of $41,344.00 and $43,500.00, respectively.
Monte Rosa Therapeutics director Ali Behbahani received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Monte Rosa Therapeutics director Andrew N. Schiff received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and were awarded as compensation, not through open-market buying or selling.
The options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options covering 25,800 underlying shares directly.
Monte Rosa Therapeutics director Anthony M. Manning received a grant of stock options for 25,800 shares of Common Stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, provided he continues in service until that time. Following this grant, he holds 25,800 derivative securities representing rights to acquire common shares.
Monte Rosa Therapeutics director Jan Skvarka received a grant of 25,800 stock options for common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. Following this grant, he holds options for 25,800 shares. The options vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as he continues serving the company.
Monte Rosa Therapeutics director Kimberly Blackwell received a grant of stock options on Common Stock. The award covers 25,800 options, each with an exercise price of $17.10 per share, giving her the right to buy an equal number of shares in the future.
These options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as she continues serving until that time. After this grant, she holds 25,800 derivative securities from this award, which expire on June 11, 2036 if not exercised.
Monte Rosa Therapeutics director Eric A. Hughes received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. This is a compensation-related equity award, not an open-market purchase.
All 25,800 options will vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Hughes holds 25,800 stock options directly.
Monte Rosa Therapeutics director Christine Siu received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to her continued service.